The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas

被引:20
作者
Koga, H [1 ]
Moriya, Y [1 ]
Akasu, T [1 ]
Fujita, S [1 ]
机构
[1] Natl Canc Ctr Hosp, Dept Surg, Chuo Ku, Tokyo 104, Japan
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 1999年 / 25卷 / 03期
关键词
carcinoembryonic antigen; CEA-doubling time; colorectal cancer; hepatic resection;
D O I
10.1053/ejso.1998.0644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: CEA-doubling time (CEA-dl) was calculated by measuring serum CEA at two voluntary points. As CEA-dt is correlated with tumour doubling time the growth rate of liver metastasis could be determined. We investigated the relationship between CEA-dt and prognosis to determine the indications for resection of liver metastasis. Methods: We examined 334 patients diagnosed with resected liver metastasis of colorectal carcinoma. Patients were divided into three categories based on CEA-dt; Group A, CEA-dr <30 days; Group B, 30 days less than or equal to CEA-dt <80 days; and Group C, CEA-dt greater than or equal to 80 days. Clinicopathological parameters, the 3-year or 5-year survival rate and the rate of recurrence were compared among the three groups. Results. In Group A, the survival time after hepatic resection was significantly shorter compared to the other groups. Furthermore, multiple liver metastasis showed slightly reduced CEA-dt levels compared with solitary metastasis, but even in patients with solitary liver metastasis, the rate of survival was poor. In 70% of Group A patients, recurrent tumour was recognized within 1 year of hepatic resection. Conclusion, When surgery for liver metastasis of colorectal cancer is considered. Group A patients should be recognized as having a poor prognosis and a high rate of recurrence after hepatic resection, and CEA-dt should be employed as a prognostic factor.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 16 条
[1]  
COLLINS VP, 1962, CANCER-AM CANCER SOC, V15, P387, DOI 10.1002/1097-0142(196203/04)15:2<387::AID-CNCR2820150222>3.0.CO
[2]  
2-5
[3]  
COLLINS VP, 1956, AMER J ROENTGENOL RA, V76, P988
[4]  
DENNIS JA, 1982, CANCER, V49, P2077
[5]   SURVIVAL AFTER LIVER RESECTION FOR SECONDARY TUMORS [J].
FOSTER, JH .
AMERICAN JOURNAL OF SURGERY, 1978, 135 (03) :389-394
[6]   DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES [J].
GOLD, P ;
FREEDMAN, SO .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) :439-+
[7]   SPECIFIC CARCINOEMBRYONIC ANTIGENS OF HUMAN DIGESTIVE SYSTEM [J].
GOLD, P ;
FREEDMAN, SO .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 122 (03) :467-&
[8]  
Korenaga D, 1997, ARCH SURG-CHICAGO, V132, P188
[9]  
MACH JP, 1974, LANCET, V2, P535
[10]  
MORIYA Y, 1991, EUR J SURG ONCOL, V17, P519